論文 - 詳細
| RRC ID | 67246 |
|---|---|
| 著者 | Togami K, Miyao A, Miyakoshi K, Kanehira Y, Tada H, Chono S. |
| タイトル | Efficient delivery to human lung fibroblasts (WI-38) of pirfenidone incorporated into liposomes modified with truncated basic fibroblast growth factor and its inhibitory effect on collagen synthesis in idiopathic pulmonary fibrosis. |
| ジャーナル | Biol Pharm Bull |
| Abstract |
In the present in vitro study, we assessed the delivery of pirfenidone incorporated into liposomes modified with truncated basic fibroblast growth factor (tbFGF) to lung fibroblasts and investigated the anti-fibrotic effect of the drug. The tbFGF peptide, KRTGQYKLC, was used to modify the surface of liposomes (tbFGF-liposomes). We used the thin-layer evaporation method, followed by sonication, to prepare tbFGF-liposomes containing pirfenidone. The cellular accumulation of tbFGF-liposomes was 1.7-fold greater than that of non-modified liposomes in WI-38 cells used as a model of lung fibroblasts. Confocal laser scanning microscopy showed that tbFGF-liposomes were widely localized in WI-38 cells. The inhibitory effects of pirfenidone incorporated into tbFGF-liposomes on transforming growth factor-β1 (TGF-β1)-induced collagen synthesis in WI-38 cells were evaluated by measuring the level of intracellular hydroxyproline, a major component of the protein collagen. Pirfenidone incorporated into tbFGF-liposomes at concentrations of 10, 30, and 100 µM significantly decreased the TGF-β1-induced hydroxyproline content in WI-38 cells. The anti-fibrotic effect of pirfenidone incorporated into tbFGF-liposomes was enhanced compared with that of pirfenidone solution. These results indicate that tbFGF-liposomes are a useful drug delivery system of anti-fibrotic drugs to lung fibroblasts for the treatment of idiopathic pulmonary fibrosis. |
| 巻・号 | 38(2) |
| ページ | 270-6 |
| 公開日 | 2015-1-1 |
| DOI | 10.1248/bpb.b14-00659 |
| PMID | 25747986 |
| MeSH | Cell Line Cell Proliferation / drug effects Collagen / metabolism Fibroblast Growth Factors / administration & dosage* Fibroblast Growth Factors / chemistry* Fibroblasts / drug effects* Fibroblasts / metabolism HEK293 Cells Humans Idiopathic Pulmonary Fibrosis / drug therapy Idiopathic Pulmonary Fibrosis / metabolism Liposomes Lung / cytology Pyridones / administration & dosage* |
| IF | 1.863 |
| オルトメトリクス指標 |
オルトメトリクス指標項目
|
| 最多言及媒体 | Patent(IFI CLAIMS) |
| 各媒体での言及数の合計 | 1 |
| 過去6か月間でのオルトメトリクス指標の変動値 | 0.0 |
| リソース情報 | |
| ヒト・動物細胞 | 293(RCB1637) WI-38(RCB0702) |